Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Estrogen Receptor Positive Tumor|HER2-positive Breast Cancer
Interventions: DRUG: Trastuzumab Pyrotinib Exemestane Dalpiciclib
Sponsor: First Affiliated Hospital of Zhejiang University